BRELUNCOL 50mg tablets medication leaflet

N03AX23 brivaracetam • Nervous system | Antiepileptics | Other antiepileptics

Brivaracetamum is a medication used for the treatment of epilepsy, specifically focal seizures with or without secondary generalization, in patients aged 4 years and older. It is an antiepileptic drug that works by binding to the synaptic vesicle protein SV2A, reducing neuronal excitability.

The medication is administered orally or intravenously, as directed by a doctor. The dosage is adjusted based on the patient's age, weight, and response to treatment.

Common side effects include drowsiness, dizziness, fatigue, and irritability. In rare cases, more severe adverse effects such as depression or suicidal thoughts may occur, requiring close monitoring of patients.

Brivaracetamum is not recommended for pregnant or breastfeeding women unless the benefits outweigh the risks. Patients should inform their doctor about all medications they are taking to avoid drug interactions.

General data about BRELUNCOL 50mg

Substance: brivaracetam

Date of last drug list: 01-06-2025

Commercial code: W71123009

Concentration: 50mg

Pharmaceutical form: tablets

Quantity: 168

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: PHAROS MT LTD. - MALTA

Holder: EGIS PARMACEUTICALS PLC - UNGARIA

Number: 16023/2025/09

Shelf life: 3 years

Pharmaceutical forms available for brivaracetam

Concentrations available for brivaracetam

100mg, 10mg, 10mg/ml, 25mg, 50mg, 75mg